Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYXBiotechnology
-$0.02 today
- Market cap
- $80.25M
- Beta
- 0.00
- P/E (TTM)
- -16.7
- EPS (TTM)
- -$0.14
Volume 0.02M
Average 0.34M
PLYX Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
Polaryx Therapeutics, Inc. Common StockNASDAQ: PLYX
Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares (diluted) declines year over year
Q1 FY2026 weighted avg shares (diluted) of 47.22M shares fell 75.1% year over year. Sequentially, it fell 0.3% from the prior quarter.
Context
- Weighted avg shares (diluted) increased in 0 of the last 2 fiscal years.
- FY2025 was the lowest annual figure in the 3 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 47.34M USD
- Year-over-year change
- -75.0%
- 2-year CAGR
- -50.0%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 47.34M | -75.0% |
| FY2024 | 2024-12-31 | 189.37M | +0.0% |
| FY2023 | 2023-12-31 | 189.37M | — |
Weighted Avg Shares (Diluted) vs competitors
How PLYX compares with its peers on the latest reported figures
- PLYX's LTM Mar 2026 weighted avg shares (diluted) of 118.33M shares is the highest of the 8 companies compared; the peer median is 21.01M shares.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
PLYXPolaryx Therapeutics, Inc. Common Stock | LTM Mar 2026 | 118.33M | — | — |
| LTM Mar 2026 | 64.63M | +7.9% | +14.8% | |
| LTM Mar 2026 | 43.78M | +3008.4% | +255.3% | |
| LTM Mar 2026 | 31.18M | +4.3% | +25.4% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | 21.01M | +341.4% | +66.1% |
| LTM Mar 2026 | 18.01M | +34.2% | +11.4% | |
| LTM Mar 2026 | 17.74M | -57.8% | -41.7% | |
| LTM Mar 2026 | 1.94M | +227.5% | +48.3% | |
| Peer median (excluding PLYX) | 21.01M | +34.2% | +25.4% | |
Competitors are the stored peer set for PLYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Gross Margin | — | — | — |
| Research & Development | 2.77M | 2.81M | 6.27M |
| Selling, General & Admin | 1.01M | 1.54M | 1.56M |
| Operating Expenses | 3.78M | 4.35M | 7.82M |
| Depreciation & Amortization | 0 | 0 | 0 |
| EBITDA | (3.78M) | (30.36M) | (8.99M) |
| EBITDA Margin | — | — | — |
| Operating Income | (3.78M) | (4.35M) | (7.82M) |
| Operating Margin | — | — | — |
| Interest Income | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 |
| Other Income / Expenses | 2K | (26M) | (1.16M) |
| Income Before Tax | (3.78M) | (30.36M) | (8.99M) |
| Pre-Tax Margin | — | — | — |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (3.78M) | (30.36M) | (8.99M) |
| Net Margin | — | — | — |
| EPS (Basic) | (0.02) | (0.16) | (0.19) |
| EPS (Diluted) | (0.02) | (0.16) | (0.19) |
| Weighted Avg Shares | 189.37M | 189.37M | 47.34M |
| Weighted Avg Shares (Diluted) | 189.37M | 189.37M | 47.34M |
Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYX
Intrinsic Alpha fair value
Locked
Current Price
$1.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.